Polykandriotis E, Schmidt V J, Kneser U, Jianming S, Boccaccini A R, Horch R E
Department of Plastic and Hand Surgery, Erlangen University Hospital, Erlangen, Germany.
Handchir Mikrochir Plast Chir. 2012 Aug;44(4):198-203. doi: 10.1055/s-0032-1321838. Epub 2012 Aug 29.
With the advent of the era of tissue engineering (TE), experimental settings have been developed that allow for a defined environment with optimised cell growth conditions and/or the production of specific substitutes. These isolated systems have been termed "bioreactors". By translating the principles of bioreactors into an in vivo context, advances in biomaterial sciences and cell biology have been merged into an integrative research concept. Even today, in the age of regenerative Medicine (RegMed) the transfer of experimental in vitro findings into a clinical in vivo approach still remains a vast challenge. In order to fulfil these specific requirements bioreactors had to be defined anew. Latest advances in areas like reconstructive medicine (the arteriovenous loop as a means of organogenesis) or modern wound management (topical negative pressure therapy as a perfusion bioreactor) give new impulses towards the translation of Reg-Med concepts into the clinical routine.
随着组织工程(TE)时代的到来,已经开发出了一些实验装置,这些装置能够提供具有优化细胞生长条件的特定环境和/或生产特定的替代物。这些孤立的系统被称为“生物反应器”。通过将生物反应器的原理转化为体内环境,生物材料科学和细胞生物学的进展已融合为一个综合研究概念。即使在当今再生医学(RegMed)时代,将体外实验结果转化为临床体内方法仍然是一个巨大的挑战。为了满足这些特定要求,生物反应器必须重新定义。重建医学(如动静脉环作为器官形成的一种手段)或现代伤口管理(局部负压疗法作为灌注生物反应器)等领域的最新进展为将Reg-Med概念转化为临床常规提供了新的动力。